China’s surprise approval of a plant-based drug for Alzheimer’s management
An alga based compound, known as GV-971, is claimed to improve cognitive function in patients with Alzheimer’s disease by changing their gut microbiota. This compound is newly developed by a biotech startup, Shanghai, China–based Green Valley Pharmaceutical Co. Pre-clinical studies in mouse studies showed that GV-971 is reducing inflammation in the brains of rodents modeled to develop Alzheimer’s-like pathology. Later, non-published clinical data from a Phase 3 study conducted in 800 people “demonstrated solid and consistent cognition improvement” among the treatment group versus a control group. Based on these results, the drug regulator approved the marketing of GV-971 in China, with the condition that more evidence is needed to show its safety and efficacy.